share_log

Private Companies Are Cisen Pharmaceutical Co., Ltd.'s (SHSE:603367) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥398m Last Week

Private Companies Are Cisen Pharmaceutical Co., Ltd.'s (SHSE:603367) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥398m Last Week

辰欣藥業(SHSE:603367)的最大股東是私營公司,在上週市值上漲了39800萬人民幣後獲得了獎勵。
Simply Wall St ·  2024/09/27 06:31

Key Insights

主要見解

  • Cisen Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • The top 4 shareholders own 52% of the company
  • 13% of Cisen Pharmaceutical is held by insiders
  • 辰欣藥業的重要私營公司所有權表明,關鍵決策受到更大公衆股東的影響
  • 前4大股東擁有該公司的52%。
  • 辰欣藥業13%的股份由內部持有者持有

A look at the shareholders of Cisen Pharmaceutical Co., Ltd. (SHSE:603367) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are private companies with 43% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

看看辰欣藥業股份的股東可以告訴我們哪個群體最有權勢。持有最大股份的群體是擁有43%所有權的私營公司。換句話說,這個群體將從他們對公司的投資中獲得最多(或者損失最多)。

As a result, private companies were the biggest beneficiaries of last week's 7.3% gain.

因此,私營企業成爲上週漲幅7.3%中受益最大的公司。

Let's take a closer look to see what the different types of shareholders can tell us about Cisen Pharmaceutical.

讓我們更仔細地看一下,不同類型的股東可以告訴我們有關辰欣藥業的什麼情況。

big
SHSE:603367 Ownership Breakdown September 26th 2024
SHSE:603367所有權拆分 2024年9月26日

What Does The Institutional Ownership Tell Us About Cisen Pharmaceutical?

機構持股情況對辰欣藥業的告知是什麼?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

We can see that Cisen Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Cisen Pharmaceutical's earnings history below. Of course, the future is what really matters.

我們可以看到,辰欣藥業確實有機構投資者;他們持有公司股票的一大部分。這可能表明公司在投資社區中具有一定的聲譽。然而,最好謹慎依賴於所謂來自機構投資者的驗證。他們有時候也會犯錯。如果多個機構同時改變對一隻股票的看法,股價可能會迅速下跌。因此,值得查看以下辰欣藥業的營業收入歷史數據。當然,未來才是真正重要的。

big
SHSE:603367 Earnings and Revenue Growth September 26th 2024
SHSE:603367於2024年9月26日的收益和營業收入增長

Cisen Pharmaceutical is not owned by hedge funds. Our data shows that Cisen Technology Group Co., Ltd. is the largest shareholder with 26% of shares outstanding. The second and third largest shareholders are Yanzhen Han and Sichuan Kelun Industry Group CO., LTD., with an equal amount of shares to their name at 10%.

辰欣藥業不是對沖基金持有。我們的數據顯示,辰欣科技集團有限公司是最大的股東,持有26%的股份。第二和第三大股東分別是Yanzhen Han和四川科倫產業集團有限公司,持有相等比例的股份,均爲10%。

On looking further, we found that 52% of the shares are owned by the top 4 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

進一步觀察發現,前四名股東持有52%的股份。換句話說,這些股東對該公司的決策有重要的發言權。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

研究機構所有權是衡量和過濾股票預期表現的好方法。分析師觀點也可以達到相同的目的。我們的信息表明,這隻股票沒有任何分析師覆蓋,所以它可能不是很出名。

Insider Ownership Of Cisen Pharmaceutical

辰欣藥業的內部股權所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司內部人員的定義可能是主觀的,並在不同的司法管轄區之間有所不同。我們的數據反映了個人內部人員,至少包括董事會成員。管理層最終向董事會負責。然而,經理們成爲執行董事會成員並不罕見,尤其是如果他們是創始人或首席執行官。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。

Our most recent data indicates that insiders own a reasonable proportion of Cisen Pharmaceutical Co., Ltd.. Insiders have a CN¥753m stake in this CN¥5.9b business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

我們最新的數據顯示,公司內部人士擁有較大比例的辰欣藥業股份。內部人士在這家59億人民幣的業務中持有75300萬人民幣的股份。這可能意味着創始人仍然擁有大量股份。您可以點擊這裏查看他們是否一直在買入或賣出。

General Public Ownership

一般大衆所有權

With a 32% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Cisen Pharmaceutical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

普通大衆擁有32%的所有權,主要由個人投資者組成,對辰欣藥業有一定影響力。儘管這一群體不能直接指揮公司,但肯定對公司的運營產生真正的影響。

Private Company Ownership

私有公司的所有權

Our data indicates that Private Companies hold 43%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我們的數據顯示,私營企業持有仙樂健康43%的股份。更深入地了解這個問題可能是值得的。如果相關方,如內部人士,對其中一傢俬營企業有興趣,這應在年度報告中披露。私營企業也可能對公司有戰略利益。

Public Company Ownership

上市公司所有權

Public companies currently own 6.1% of Cisen Pharmaceutical stock. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

上市公司目前擁有辰欣藥業6.1%的股份。我們不能確定,但很可能這是一種戰略性持股。這些企業可能相似,或者協同合作。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Cisen Pharmaceutical (of which 1 is a bit concerning!) you should know about.

我發現了解一家公司的股東情況非常有趣。但要真正獲得洞察,我們還需要考慮其他信息。比如風險。每家公司都有風險,我們已經發現了辰欣藥業的2個警示信號(其中1個有點令人擔憂!),你應該知道。

Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.

當然,這可能不是最好的購買股票。因此,查看這份免費免費的有趣公司列表可能會有所幫助。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論